НАЗВАНИЕ СТАТЬИ «РОЛЬ ЭСТРОГЕНА В ТЕЧЕНИИ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ»

Subject Terms: эстроген, аутоиммунные заболевания, иммунитет, системная красная волчанка, ревматоидный артрит, гормоны, иммуномодуляция, B-лимфоциты, Th2-ответ, беременность, менопауза, аутоантитела, иммунная система, женский пол, воспаление

НАЗВАНИЕ СТАТЬИ «РОЛЬ ЭСТРОГЕНА В ТЕЧЕНИИ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ»

Subject Terms: эстроген, аутоиммунные заболевания, иммунитет, системная красная волчанка, ревматоидный артрит, гормоны, иммуномодуляция, B-лимфоциты, Th2-ответ, беременность, менопауза, аутоантитела, иммунная система, женский пол, воспаление

CLINICAL AND MORPHOLOGICAL CHARACTERISTICS AND EFFECTIVENESS OF TREATMENT OF PATIENTS WITH LUPUS NEPHRITIS (EXPERIENCE OF ONE CENTER)

Authors: Nina Yu. Romazina, Alisher Yu. Dodojonov, Semyon S. Osmolovsky, Nikita K. Fonarev, Anna O. Lazuchenko, Mary A. Gambaryan, Elena V. Rozhanskaya, Natalia O. Krasnikova, Galina M. Orlova

Source: Байкальский медицинский журнал, Vol 4, Iss 1, Pp 11-17 (2025)

Subject Terms: системная красная волчанка, волчаночный гломерулонефрит, морфологический класс iv, эффективность лечения, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.bmjour.ru/jour/article/view/261; https://doaj.org/toc/2949-0715

Access URL: https://doaj.org/article/7e1185d2531c4f77989156024aedc8f9

CLİNİCAL AND LABORATORY RELATİONSHİPS İN PATİENTS WİTH DİFFERENT VARİANTS OF SYSTEMİC LUPUS ERYTHEMATOSUS ; КЛИНИКО-ЛАБОРАТОРНЫЕ ВЗАИМОСВЯЗИ У ПАЦИЕНТОВ С РАЗЛИЧНЫМИ ВАРИАНТАМИ ТЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ ; SİSTEMALİ QİZİL VOLCHANKANİNG TURLİ KECHİSH VARİANTLARİDA KLİNİK VA LABORATOR O‘ZARO BOG‘LİQLİKLAR

Authors: Sultanova , Mahsuma

Source: Eurasian Journal of Medical and Natural Sciences; Vol. 5 No. 10 Part 2 (2025): Eurasian Journal of Medical and Natural Sciences; 23-32 ; Евразийский журнал медицинских и естественных наук; Том 5 № 10 Part 2 (2025): Евразийский журнал медицинских и естественных наук; 23-32 ; Yevrosiyo tibbiyot va tabiiy fanlar jurnali; Jild 5 Nomeri 10 Part 2 (2025): Евразийский журнал медицинских и естественных наук; 23-32 ; 2181-287X

Subject Terms: Системная красная волчанка, вероятная системная красная волчанка, тест волчаночной полоски, Systemic lupus erythematosus, probable systemic lupus erythematosus, lupus strip test, Sistemali qizil volchanka, taxminiy sistemali qizil volchanka, volchanka polosasi testi

File Description: application/pdf

Relation: https://in-academy.uz/index.php/EJMNS/article/view/63417/39890

Availability: https://in-academy.uz/index.php/EJMNS/article/view/63417

CYTOKINE STORM IN SLE: MECHANISMS OF IMMUNOINFLAMMATION AND THERAPEUTIC OPPORTUNITIES ; ЦИТОКИНОВЫЙ ШТОРМ ПРИ СКВ: МЕХАНИЗМЫ ИММУНОВОСПАЛЕНИЯ И ТЕРАПЕВТИЧЕСКИЕ ВОЗМОЖНОСТИ

Authors: Мухитдинова , Гулшан, Кенжаева, Дилобар

Source: Eurasian Journal of Medical and Natural Sciences; Vol. 5 No. 11 (2025): Eurasian Journal of Medical and Natural Sciences; 187-193 ; Евразийский журнал медицинских и естественных наук; Том 5 № 11 (2025): Евразийский журнал медицинских и естественных наук; 187-193 ; Yevrosiyo tibbiyot va tabiiy fanlar jurnali; Jild 5 Nomeri 11 (2025): Евразийский журнал медицинских и естественных наук; 187-193 ; 2181-287X

Subject Terms: Цитокиновый шторм, системная красная волчанка, IL-6, IL-1β, TNF-α, таргетная терапия, персонализированный подход, Cytokine storm, systemic lupus erythematosus, targeted therapy, personalized approach

File Description: application/pdf

Relation: https://in-academy.uz/index.php/EJMNS/article/view/66261/41659

Availability: https://in-academy.uz/index.php/EJMNS/article/view/66261

Системная Красная Волчанка И Неврологические Осложнения

Authors: Комилжоновна , Хамдамова Бахора, Мамрайим угли , Рахмонов Мухриддин

Source: World of Medicine : Journal of Biomedical Sciences; Vol. 2 No. 10 (2025): World of Medicine : Journal of Biomedical Sciences; 82-88 ; 2960-9356

Subject Terms: системная красная волчанка, неврологические осложнения, лечение, диагностика, ЦНС

File Description: application/pdf

Relation: https://wom.semanticjournals.org/index.php/biomed/article/view/527/453; https://wom.semanticjournals.org/index.php/biomed/article/view/527

Availability: https://wom.semanticjournals.org/index.php/biomed/article/view/527

CLINICAL FEATURES OF GASTROINTESTINAL TRACT LESIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ; КЛИНИЧЕСКИЕ ОСОБЕННОСТИ ПОРАЖЕНИЯ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТА У ПАЦИЕНТОВ С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ ; TIZIMLI QIZIL YUGURUK BILАN OGʼRIGАN BEMORLАRDА OSHQOZON-ICHАK TRАKTI ZARARLANISHINING KLINIK XUSUSIYATLАRI

Authors: Iskanova, Gulshan, Egamova, Sayyora, Israilova, Nigora

Source: Medical science of Uzbekistan; No. 2 (2025): March-April; 32-34 ; Медицинская наука Узбекистана; № 2 (2025): Март-Апрель; 32-34 ; O`zbekiston tibbiyot ilmi; No. 2 (2025): Mart-Aprel; 32-34 ; 2181-3612

Subject Terms: Systemic lupus erythematosus, glucocorticosteroids, gastrointestinal pathology, Системная красная волчанка, глюкокортикостероиды, гастроинтестинальная патология, tizimli qizil yuguruk, glyukokortikosteroidlar, oshqozon-ichak patologiyasi

File Description: application/pdf

Relation: https://fdoctors.uz/index.php/journal/article/view/112/81; https://fdoctors.uz/index.php/journal/article/view/112

Availability: https://fdoctors.uz/index.php/journal/article/view/112
https://doi.org/10.56121/2181-3612-2025-2-32-34

Assessment of antiphospholipid antibodies using enzyme-linked immunosorbent assay and chemiluminescent method ; Исследование антифосфолипидных антител иммуноферментным и хемилюминесцентным методами

Authors: T. M. Reshetnyak, M. V. Cherkasova, F. A. Cheldieva, K. S. Nurbaeva, A. M. Lila, Т. М. Решетняк, М. В. Черкасова, Ф. А. Чельдиева, К. С. Нурбаева, А. М. Лила

Contributors: The article was prepared as part of the fundamental scientific topic PK 125020501434-1, Статья подготовлена в рамках фундаментальной научной темы РК 125020501434-1

Source: Modern Rheumatology Journal; Том 19, № 2 (2025); 32-38 ; Современная ревматология; Том 19, № 2 (2025); 32-38 ; 2310-158X ; 1996-7012

Subject Terms: антитела к кардиолипину, antiphospholipid syndrome, systemic lupus erythematosus, immunosorbent analysis, chemiluminated analysis, antibodies against β2 -glycoprotein 1, antibodies against cardiolipin, антифосфолипидный синдром, системная красная волчанка, иммуноферментный анализ, хемилюминисцентный анализ, антитела к β2 -гликопротеину 1

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1737/1581; Arachchillage DRJ, Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol. 2017 Jul;178(2): 181-195. doi:10.1111/bjh.14632.; Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep; 71(9):1400-1412. doi:10.1002/art.40930.; Asherson RA. New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS"). Autoimmun Rev. 2006 Dec;6(2):76-80. doi:10.1016/j.autrev.2006.06.008.; Atsumi T, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies – are they worth assaying? Thromb Res. 2004;114(5-6):533-8. doi:10.1016/j.thromres.2004.08.024.; Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x.; Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005 Feb;93(2):289-97. doi:10.1160/TH04-06-0382.; Bidot CJ, Jy W, Horstman LL, et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol. 2003 Feb;120(4):618-26. doi:10.1046/j.1365-2141.2003.04161.x.; De Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost. 2010 Jul;8(7):1540-6. doi:10.1111/j.1538-7836.2010.03857.x. Epub 2010 Mar 16.; Александрова ЕН, Новиков АА, Решетняк ТМ и др. Антитела к 2-гликопротеину 1 и антитела к кардиолипину при антифосфолипидном синдроме: анализ чувствительности и специфичности. Клиническая медицина. 2003;(9):25-31.; Реброва ОЮ. Статистическии анализ медицинских данных. Применение пакета прикладных программ STATISTICA. Москва: МедиаСфера; 2002.; https://telemedai.ru/biblioteka-dokumentov/klinicheskie-ispytaniya-programmnogoobespecheniya-na-osnove-intellektualnyhtehnologij-luchevaya-diagnostika; Barbhaiya M, Zuily S, Naden R, et al. ACR/EULAR APS Classification Criteria Collaborators. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. 2023 Oct;75(10): 1687-1702. doi:10.1002/art.42624.; Devreese KMJ, Bertolaccini ML, Branch DW, et al. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Anti phospholipid Antibodies. J Thromb Haemost. 2024 Nov 5:S1538-7836(24)00638-X. doi:10.1016/j.jtha.2024.10.022.; Atsumi T, Chighizola CB, Fujieda Y, et al. 16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends. Lupus. 2023 Dec;32(14):1625-1636. doi:10.1177/09612033231211820.; Forastiero R, Papalardo E, Watkins M, et al. Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta. 2014 Jan 20;428: 99-105. doi:10.1016/j.cca.2013.11.009.; Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? Semin Thromb Hemost. 2008 Jun;34(4):340-6. doi:10.1055/s-0028-1085476.; Sciascia S, Montaruli B, Infantino M. Antiphospholipid antibody testing. Med Clin (Barc). 2024 Aug;163 Suppl 1:S4-S9. doi:10.1016/j.medcli.2024.06.002.; Van Hoecke F, Persijn L, Decavele AS, Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2012 Dec;34(6):630-40. doi:10.1111/j.1751-553X.2012.01448.x.; Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020 Nov;18(11): 2828-2839. doi:10.1111/jth.15047.; Ткаченко ОЮ, Лапин СВ, Лазарева НМ и др. Сравнительный анализ информативности тест-систем разных производителей для определения антифосфолипидных антител для диагностики антифосфолипидного синдрома. Клиническая лабораторная диагностика. 2017;62(1):40-4.; Zhang S, Wu Z, Li P, et al. Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome. Medicine (Baltimore). 2015 Nov;94(46):e2059. doi:10.1097/MD.0000000000002059.; Borghi MO, Beltagy A, Garrafa E, et al. Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Front Immunol. 2020 Oct 15;11:584241. doi:10.3389/fimmu.2020.584241.; Oku K, Amengual O, Kato M, et al. Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. Thromb Res. 2016 Oct;146:1-6. doi:10.1016/j.thromres.2016.08.018.; Capozzi A, Lococo E, Grasso M, et al. Detection of antiphospholipid antibodies by automated chemiluminescence assay. J Immunol Methods. 2012 May 31;379(1-2):48-52. doi:10.1016/j.jim.2012.02.020.; Волкова МВ, Кундер ЕВ, Генералов ИИ, Роггенбук Д. Антифосфолипидные антитела: современные представления о патогенетическом действии и лабораторной диагностике. Вестник Витебского государственного медицинского университета 2015;(14-3):6-15.

Availability: https://mrj.ima-press.net/mrj/article/view/1737
https://doi.org/10.14412/1996-7012-2025-2-32-38

Clinical features of systemic lupus erythematosus in men depending on testosterone level ; Клинические особенности системной красной волчанки у мужчин в зависимости от уровня тестостерона

Authors: T. S. Panevin, T. V. Popkova, E. G. Zotkin, S. I. Glukhova, M. E. Diatroptov, Т. С. Паневин, Т. В. Попкова, Е. Г. Зоткин, С. И. Глухова, М. Е. Диатроптов

Contributors: The article was prepared as part of the basic scientific topic “Immunopathology and therapeutic approaches in systemic rheumatic diseases” №125020501434-1, Статья подготовлена в рамках фундаментальной научной темы «Изучение иммунопатологии и подходы к терапии при системных ревматических заболеваниях» №125020501434-1

Source: Modern Rheumatology Journal; Том 19, № 2 (2025); 63-69 ; Современная ревматология; Том 19, № 2 (2025); 63-69 ; 2310-158X ; 1996-7012

Subject Terms: системная красная волчанка, hypogonadism, systemic lupus erythematosus, гипогонадизм

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1741/1585; Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412.; Christou EAA, Banos A, Kosmara D, et al. Sexual dimorphism in SLE: above and beyond sex hormones. Lupus. 2019 Jan;28(1):3-10. doi:10.1177/0961203318815768. Epub 2018 Dec 1.; Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nat Rev Rheumatol. 2020 Nov;16(11):628-644. doi:10.1038/s41584-020-0503-4. Epub 2020 Oct 2.; Клюквина НГ. Системная красная волчанка у мужчин: клиника, течение, исходы. Автореф. дисс. докт. мед. наук. Москва; 2010. 52 с.; Фоломеев МЮ, Мирочицкий СН, Алекберова ЗС. Особенности течения системной красной волчанки у мужчин. Терапевтический архив. 1981;53(7):30-33.; Folomeev M, Kosheleva N, Alekberova Z. Systemic lupus erythematosus associated with Klinefelter's syndrome – a case report from the USSR. J Rheumatol. 1991 Jun; 18(6):940-1.; Lavalle C, Loyo E, Paniagua R, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol. 1987 Apr; 14(2):268-72.; Дедов ИИ, Мокрышева НГ, Мельниченко ГА, и др. Проект клинических рекомендаций «Синдром гипогонадизма у мужчин». Ожирение и метаболизм. 2021;18(4): 496-507.; Паневин ТС, Роживанов РВ, Насонов ЕЛ. Синдром гипогонадизма у мужчин с воспалительными заболеваниями суставов. Терапевтический архив. 2023;95(5): 429-433.; Baillargeon J, Al Snih S, Raji MA, et al. Hypogonadism and the risk of rheumatic autoimmune disease. Clin Rheumatol. 2016 Dec;35(12):2983-2987. doi:10.1007/s10067-016-3330-x. Epub 2016 Jun 20.; Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endo crinol Metab. 2004 Jul;89(7):3313-8. doi:10.1210/jc.2003-031069.; Cutolo M, Sulli A, Capellino S, et al. Anti-TNF and sex hormones. Ann N Y Acad Sci. 2006 Jun:1069:391-400. doi:10.1196/annals.1351.037.; Паневин ТС, Роживанов РВ, Зоткин ЕГ и др. Синдром гипогонадизма у мужчин при воспалительных заболеваниях суставов: частота и клинические особенности. Терапевтический архив. 2024; 96(5): 486-493.; Stahl NI, Decker JL. Androgenic status of males with systemic lupus erythematosus. Arthritis Rheum. 1978 Jul-Aug;21(6):665-8. doi:10.1002/art.1780210609.; Inman RD, Jovanovic L, Markenson JA, et al. Systemic lupus erythematosus in men. Genetic and endocrine features. Arch Intern Med. 1982 Oct;142(10):1813-5.; Miller MH, Urowitz MB, Gladman DD, Killinger DW. Systemic lupus erythematosus in males. Medicine (Baltimore). 1983 Sep;62(5):327-34. doi:10.1097/00005792-198309000-00005.; Arnaud L, Nordin A, Lundholm H, et al. Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. Arthritis Rheumatol. 2017 Jun;69(6):1272-1279. doi:10.1002/art.40057. Epub 2017 May 4.; Шабанова СШ, Ананьева ЛП, Алекберова ЗС. Терапия циклофосфаном и овариальная недостаточность у больных системной красной волчанкой. Научнопрактическая ревматология. 2003; 41(3):63-67.; Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamideinduced azoospermia. Ann Intern Med. 1997 Feb 15;126(4):292-5. doi:10.7326/0003-4819-126-4-199702150-00005.; Mok CC, Lau CS. Profile of sex hormones in male patients with systemic lupus erythema tosus. Lupus. 2000;9(4):252-7. doi:10.1191/096120300680198926.; Folomeev M, Dougados M, Beaune J, et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus. 1992 May;1(3):191-5. doi:10.1177/096120339200100312.; Фоломеев МЮ, Полынцев ЮВ. Применение андрогенов в комплексном лечении мужчин, больных системной красной волчанкой. Ревматология. 1986;(4):24-26.; Zheng Z, Pan J, Liu M, et al. Anemia and testosterone deficiency risk: insights from NHANES data analysis and a Mendelian randomization analysis. Aging Male. 2024 Dec; 27(1):2346312. doi:10.1080/13685538.2024.2346312. Epub 2024 Apr 29.

Availability: https://mrj.ima-press.net/mrj/article/view/1741
https://doi.org/10.14412/1996-7012-2025-2-63-69

On the clinical meaning of proliferative activity of B-lymphocytes in a systemic lupus erythematosus

Source: Scientific and practical specialized journal "Rheumatology of Kazakhstan". :6-9

Subject Terms: systemic lupus erythematosus, спонтанная пролиферативная активность В-лимфоцитов, spontaneous proliferative activation in B-lymphocytes, системная красная волчанка, 3. Good health

Spontaneous immunoglobulin-synthesizing activity of B-lymphocytes at various clinical variants of systemic red lupus

Source: Scientific and practical specialized journal "Rheumatology of Kazakhstan". :36-40

Subject Terms: SIAL, системная красная волчанка, immunoglobulin, спонтанная иммуноглобулинсинтезирующая активность В-лимфоцитов, AS, 3. Good health

Advances in rheumatology at the beginning of the 21st century

Authors: E. L. Nasonov, A. M. Lila, T. V. Dubinina, O. A. Nikininskaya, V. N. Amirdjanova

Source: Научно-практическая ревматология, Vol 60, Iss 1, Pp 5-20 (2022)

Subject Terms: иммуновоспалительные ревматические заболевания, 03 medical and health sciences, 0302 clinical medicine, RC925-935, коронавирусная болезнь 2019, ревматоидный артрит, системная красная волчанка, Diseases of the musculoskeletal system

Access URL: https://rsp.mediar-press.net/rsp/article/download/3111/2151
https://doaj.org/article/ec58a97f031b44efa7068e769794ad62

Поражение печени при системной красной волчанке у подростков

Authors: Bohmat, L.F., Shevchenko, N.S., Matviienko, Ye.V.

Source: Zdorovʹe Rebenka, Vol 10, Iss 4.64, Pp 36-40 (2015)
CHILD`S HEALTH; № 4.64 (2015); 36-40
Здоровье ребенка-Zdorovʹe rebenka; № 4.64 (2015); 36-40
Здоров'я дитини-Zdorovʹe rebenka; № 4.64 (2015); 36-40

Subject Terms: systemic lupus erythematosus, системний червоний вовчак, підлітки, печінка, фіброгенез, adolescents, liver, fibrogenesis, системная красная волчанка, подростки, печень, фиброгенез, Pediatrics, RJ1-570, 3. Good health

File Description: application/pdf

Access URL: https://doaj.org/article/f064924f0cd3481cb970320d03b81e59
http://childshealth.zaslavsky.com.ua/article/view/75242

ОСОБЕННОСТИ ПОРАЖЕНИЯ ЛЕГКИХ У ПАЦИЕНТОВ С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ

Authors: Атоева Мунисхон Набиевна

Source: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 3 No. 5 (2024): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 311-318 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 3 № 5 (2024): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 311-318 ; 2181-3469

Subject Terms: системная красная волчанка, поражение дыхательной системы, легочный васкулит, мультиспиральная компьютерная томография, цветовая фильтрация

File Description: application/pdf

Relation: https://sciencebox.uz/index.php/amaltibbiyot/article/view/10680/9750; https://sciencebox.uz/index.php/amaltibbiyot/article/view/10680

Availability: https://sciencebox.uz/index.php/amaltibbiyot/article/view/10680

Mental disorders in children with rheumatic diseases ; Нарушения психического здоровья у детей с ревматическими заболеваниями

Authors: A. V. Santimov, S. V. Grechanyi, G. A. Novik, А. В. Сантимов, С. В. Гречаный, Г. А. Новик

Source: Rheumatology Science and Practice; Vol 62, No 1 (2024); 109-117 ; Научно-практическая ревматология; Vol 62, No 1 (2024); 109-117 ; 1995-4492 ; 1995-4484

Subject Terms: генно-инженерные биологические препараты, juvenile idiopathic arthritis, juvenile-onset systemic lupus erythematosus, juvenile primary fibromyalgia, anxiety, depression, psychotherapy, psychopharmacotherapy, biological disease-modifying antirheumatic drugs, ювенильный идиопатический артрит, системная красная волчанка с ювенильным дебютом, ювенильная первичная фибромиалгия, тревога, депрессия, психотерапия, психофармакотерапия

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3520/2355; Kostev K, Teichgräber F, Konrad M, Jacob L. Association between chronic somatic conditions and depression in children and adolescents: A retrospective study of 13,326 patients. J Affect Disord. 2019;245:697-701. doi:10.1016/j.jad.2018.11.014; Williams NA, Burnfield JM. Psychological difficulties and parental well-being in children with musculoskeletal problems in the 2011/2012 National Survey of Children’s Health. Rehabil Psychol. 2019;64(1):87-97. doi:10.1037/rep0000251; Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. doi:10.1038/nri.2015.5; Suneson K, Lindahl J, Chamli Hårsmar S, Söderberg G, Lindqvist D. Inflammatory depression-mechanisms and non-pharmacological interventions. Int J Mol Sci. 2021;22(4):1640. doi:10.3390/ijms22041640; Davis AM, Rubinstein TB, Rodriguez M, Knight AM. Mental health care for youth with rheumatologic diseases – bridging the gap. Pediatr Rheumatol Online J. 2017;15(1):85. doi:10.1186/s12969-017-0214-9; Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. doi:10.1016/S0140-6736(07)60363-8; Korte-Bouws GAH, Albers E, Voskamp M, Hendriksen H, de Leeuw LR, Güntürkün O, et al. Juvenile arthritis patients suffering from chronic inflammation have increased activity of both IDO and GTP-CH1 pathways but decreased BH4 efficacy: Implications for well-being, including fatigue, cognitive impairment, anxiety, and depression. Pharmaceuticals (Basel). 2019;12(1):9. doi:10.3390/ph12010009; Reda MM, Hosny E, AbuSenna H. Psychiatric morbidity in patients with rheumatoid juvenile arthritis: A SPECT study. Middle East Curr Psychiat. 2011;18(3):132-137. doi:10.1097/01.XME.0000398422.59986.78; Hanns L, Cordingley L, Galloway J, Norton S, Carvalho LA, Christie D, et al. Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford). 2018;57(8):1381-1389. doi:10.1093/rheumatology/key088; El-Najjar AR, Negm MG, El-Sayed WM. The relationship between depression, disease activity and physical function in juvenile idiopathic arthritis patients in Zagazig University Hospitals – Egypt. Egypt Rheumatologist. 2014;36(3):145-150. doi:10.1016/j.ejr.2014.01.001; Tarakci E, Yeldan I, Kaya Mutlu E, Baydogan SN, Kasapcopur O. The relationship between physical activity level, anxiety, depression, and functional ability in children and adolescents with juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(11):1415-1420. doi:10.1007/s10067-011-1832-0; Fair DC, Rodriguez M, Knight AM, Rubinstein TB. Depression and anxiety in patients with juvenile idiopathic arthritis: Current insights and impact on quality of life, a systematic review. Open Access Rheumatol. 2019;11:237-252. doi:10.2147/OARRR. S174408; Сантимов АВ, Часнык ВГ, Гречаный СВ. Психометрическая оценка хронического болевого синдрома при ювенильном идиопатическом артрите. Педиатр. 2019;10(3):25-30. [Santimov AV, Chasnyk VG, Grechanyi SV. Psychometric assessment of chronic pain syndrome in juvenile idiopathic arthritis. Pediatrician (St. Petersburg). 2019;10(3):25-30 (In Russ.)]. doi:10.17816/PED10325-30; Сантимов АВ, Часнык ВГ, Гречаный СВ. Уровень тревоги и депрессии у детей и подростков с хроническим болевым синдромом (на примере ювенильного идиопатического артрита). Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2019;4-2:78-86. doi:10.31363/2313-7053-2019-4-2-78-86; Зубарева ЕС, Генералова ДД, Сантимов АВ, Новик ГА, Тамразова ОБ, Гречаный СВ. Выявление нарушений психического здоровья при ювенильном идиопатическом артрите с хроническим болевым синдромом. Педиатрия им. Г.Н. Сперанского. 2023;102(4):147-158. doi:10.24110/0031-403X-2023-102-4-147-158; Kyllönen MS, Ebeling H, Kautiainen H, Puolakka K, Vähäsalo P. Psychiatric disorders in incident patients with juvenile idiopathic arthritis – a case-control cohort study. Pediatr Rheumatol Online J. 2021;19(1):105. doi:10.1186/s12969-021-00599-x; Berthold E, Dahlberg A, Jöud A, Tydén H, Månsson B, Kahn F, et al. The risk of depression and anxiety is not increased in individuals with juvenile idiopathic arthritis – results from the SouthSwedish Juvenile Idiopathic Arthritis Cohort. Pediatr Rheumatol Online J. 2022;20(1):114. doi:10.1186/s12969-022-00765-9; Delcoigne B, Horne A, Reutfors J, Askling J. Risk of psychiatric disorders in juvenile idiopathic arthritis: Population- and siblingcontrolled cohort and cross-sectional analyses. ACR Open Rheumatol. 2023;5(5):277-284. doi:10.1002/acr2.11549; Mann CM, Schanberg LE, Wang M, von Scheven E, Lucas N, Hernandez A, et al. Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. Qual Life Res. 2020;29(9):2573-2584. doi:10.1007/s11136-020-02513-6; Kısaarslan AP, Çiçek SÖ, Batu ED, Şahin S, Gürgöze MK, Çetinkaya SB, et al. Neuropsychiatric involvement in juvenileonset systemic lupus erythematosus: A multicenter study. Joint Bone Spine. 2023;90(4):105559. doi:10.1016/j.jbspin.2023.105559; Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi:10.1186/s40348-023-00161-7; Donnelly C, Cunningham N, Jones JT, Ji L, Brunner HI, Kashikar-Zuck S. Fatigue and depression predict reduced health-related quality of life in childhood-onset lupus. Lupus. 2018;27(1):124- 133. doi:10.1177/0961203317716317; Каледа МИ, Никишина ИП. Нейропсихические нарушения при системной красной волчанке с ювенильным дебютом. Научно-практическая ревматология. 2020;58(4):437-442. doi:10.47360/1995-4484-2020-437-442; Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ.Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177. doi:10.14412/1995-4484-2020-171-177; Кучинская ЕМ, Яковлева ЮА, Ракова МА, Любимова НА, Суспицын ЕН, Костик ММ. Системная красная волчанка с нейропсихическими проявлениями у ребенка: описание клинического случая и обзор международных рекомендаций по диагностике и лечению. Российский вестник перинатологии и педиатрии. 2021;66(1):98-105. doi:10.21508/1027-4065-2021-66-1-98-105; Кучинская ЕМ, Часнык ВГ, Костик ММ. Системная красная волчанка у детей: применение формализованных методов описания течения и исхода заболевания в ретроспективном исследовании. Педиатр. 2017;8(5):35-43. doi:10.17816/PED8535-43; Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al.; UK JSLE Cohort Study. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus. 2021;30(12):1955-1965. doi:10.1177/09612033211045050; Knight AM, Xie M, Mandell DS. Disparities in psychiatric diagnosis and treatment for youth with systemic lupus erythematosus: Analysis of a national US Medicaid sample. J Rheumatol. 2016;43(7):1427-1433. doi:10.3899/jrheum.150967; Coles ML, Weissmann R, Uziel Y. Juvenile primary fibromyalgia syndrome: Epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis. Pediatr Rheumatol Online J. 2021;19(1):22. doi:10.1186/s12969-021-00493-6; Kashikar-Zuck S, Parkins IS, Graham TB, Lynch AM, Passo M, Johnston M, et al. Anxiety, mood, and behavioral disorders among pediatric patients with juvenile fibromyalgia syndrome. Clin J Pain. 2008;24(7):620-626. doi:10.1097/AJP.0b013e31816d7d23; Conte PM, Walco GA, Kimura Y. Temperament and stress response in children with juvenile primary fibromyalgia syndrome. Arthritis Rheum. 2003;48(10):2923-2930. doi:10.1002/art.11244; Kashikar-Zuck S, Cunningham N, Peugh J, Black WR, Nelson S, Lynch-Jordan AM, et al. Long-term outcomes of adolescents with juvenile-onset fibromyalgia into adulthood and impact of depressive symptoms on functioning over time. Pain. 2019;160(2):433-441. doi:10.1097/j.pain.0000000000001415; Connelly M, Weiss JE. Pain, functional disability, and their association in juvenile fibromyalgia compared to other pediatric rheumatic diseases. Pediatr Rheumatol. 2019;17(1):72. doi:10.1186/s12969-019-0375-9; Weiss JE, Schikler KN, Boneparth AD, Connelly M. Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Pediatr Rheumatol. 2019;17(1):1-8. doi:10.1186/s12969-019-0356-z; Siegel DM, Janeway D, Baum J. Fibromyalgia syndrome in children and adolescents: Clinical features at presentation and status at follow-up. Pediatrics. 1998;101(3 Pt 1):377-382. doi:10.1542/peds.101.3.377; Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221-227. doi:10.1001/archinte.160.2.221; Gmuca S, Sherry DD. Fibromyalgia: Treating pain in the juvenile patient. Pediatr Drugs. 2017;19(4):325-338. doi:10.1007/s40272-017-0233-5; Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol. 2006;2(8):416-424. doi:10.1038/ncprheum0245; Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum. 2012;64(1):297-305. doi:10.1002/art.30644; Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2018;9(9):CD003968. doi:10.1002/14651858.CD003968.pub5; Сантимов АВ, Часнык ВГ, Гречаный СВ. Психотерапевтический подход к лечению хронического болевого синдрома при ювенильном идиопатическом артрите и предикторы его эффективности. Психиатрия, психотерапия и клиническая психология. 2022;13(2):138-150. doi:10.34883/PI.2022.13.2.010; Trachtman R, Samuels J, Wojtal E, Feldman BM. Resilience and its associations in children with systemic lupus erythematosus and juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2023;21(1):67. doi:10.1186/s12969-023-00854-3; Ross E, Abulaban K, Kessler E, Cunningham N. Non-pharmacologic therapies in treatment of childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2022;31(7):864-879. doi:10.1177/09612033221094704; Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16(9):1347-1368. doi:10.1517/14656566.2015.1047343; Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2(2):CD010292. doi:10.1002/14651858.CD010292.pub2; Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):27. doi:10.1186/s12969-019-0325-6; Arnold LM, Bateman L, Palmer RH, Lin Y. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: Lessons from a clinical trial program. Pediatr Rheumatol Online J. 2015;13:27. doi:10.1186/s12969-015-0025-9; Mariutto EN, Stanford SB, Kashikar-Zuck S, Welge JA, Arnold LM. An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia. J Clin Psychopharmacol. 2012;32(2):293-295. doi:10.1097/JCP.0b013e31824858dc; Nishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, et al. Amitriptyline in the treatment of fibromyalgia: A systematic review of its efficacy. Rheumatology (Oxford). 2008;47(12):1741-1746. doi:10.1093/rheumatology/ken317; Migliorini F, Maffulli N, Knobe M, Tenze G, Aljalloud A, Colarossi G. Pregabalin administration in patients with fibromyalgia: A Bayesian network meta-analysis. Sci Rep. 2022;12(1):12148. doi:10.1038/s41598-022-16146-x; Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336-1344. doi:10.1002/art.22457; Egunsola O, Wylie CE, Chitty KM, Buckley NA. Systematic review of the efficacy and safety of gabapentin and pregabalin for pain in children and adolescents. Anesth Analg. 2019;128(4):811-819. doi:10.1213/ANE.0000000000003936; Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, BhadraBrown P, et al.; Pregabalin Adolescent Fibromyalgia Study Group. Safety and efficacy of pregabalin in adolescents with fibromyalgia: A randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14(1):46. doi:10.1186/s12969-016-0106-4; Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. Int J Mol Sci. 2020;21(6):2194. doi:10.3390/ijms21062194; Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318-327. doi:10.14412/1995-4484-2019-318-327; Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: Towards precision medicine. Nat Rev Drug Discov. 2022;21(3):224-244. doi:10.1038/s41573-021-00368-1; Лисицына ТА, Абрамкин АА, Вельтищев ДЮ, Серавина ОФ, Ковалевская ОБ, Борисова АБ, и др. Эффективность олокизумаба в отношении коморбидного депрессивного расстройства у больных ревматоидным артритом: предварительные результаты исследования. Научно-практическая ревматология. 2023; 61(2):188-198. doi:10.47360/1995-4484-2023-188-198; Coskun Benlidayi I. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int. 2019;39(5):781-791. doi:10.1007/s00296-019-04251-6; Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol. 2016;290:22-25. doi:10.1016/j.jneuroim.2015.11.011; Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – A controlled cross-sectional study. Cytokine. 2016;84:25-28. doi:10.1016/j.cyto.2016.05.011; Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, et al. Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol. 2013;31(6 Suppl 79):S60-S63.; Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa Al, et al. Low-grade chronic inflammation mediated by mast cells in fibromyalgia: Role of IL-37. J Biol Regul Homeost Agents. 2018;32(2):195-198.; Loncharich MF, Robertson I. Anifrolumab in systemic lupus erythematosus. Drugs Today (Barc). 2023;59(2):53-61. doi:10.1358/dot.2023.59.2.3521876; Алексеева ЕИ, Денисова РВ, Валиева СИ, Бзарова ТМ, Слепцова ТВ, Чомахидзе АМ, и др. Эффективность и безопасность ритуксимаба у детей с системной красной волчанкой: результаты ретроспективного исследования серии случаев. Вопросы современной педиатрии. 2016;15(5):497-504. doi:10.15690/vsp.v15i5.1624; Калашникова ЭМ, Раупов РК, Любимова НА, Кучинская ЕМ, Масалова ВВ, Исупова ЕА, и др. Опыт применения ритуксимаба у пациентов с ювенильной системной красной волчанкой: предварительные результаты двуцентрового когортного исследования. Российский вестник перинатологии и педиатрии. 2023;68(1):74-84. doi:10.21508/1027-4065-2023-68-1-74-84; Santimov A, Grom AA. Other biological therapies for pediatric rheumatic diseases. Handbook Syst Autoimmun Dis. 2016;11:503-525. doi:10.1016/B978-0-444-63596-9.00024-4; Plüß M, Tampe B, Niebusch N, Zeisberg M, Müller GA, Korsten P. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne). 2020;7:222. doi:10.3389/fmed.2020.00222; Cheng H, Zhang XY, Yang HD, Yu Z, Yan CL, Gao C, et al. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol. 2022;13:911730. doi:10.3389/fimmu.2022.911730; Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. Patient Relat Outcome Meas. 2019;10:1-7. doi:10.2147/PROM.S134326; Xu Y, Xu JW, Wang YJ, Tung TH, Chien CW. Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and metaanalysis of randomised controlled trials. Int Immunopharmacol. 2022;109:108811. doi:10.1016/j.intimp.2022.108811

Availability: https://rsp.mediar-press.net/rsp/article/view/3520
https://doi.org/10.47360/1995-4484-2024-109-117

Pro-inflammatory activation of monocytes in patients with immunoinflammatory rheumatic diseases ; Провоспалительная активация моноцитов у пациентов с иммуновоспалительными ревматическими заболеваниями (предварительные результаты)

Authors: A. I. Bogatyreva, E. V. Gerasimova, T. V. Kirichenko, Yu. V. Markina, T. V. Popkova, M. V. Shalygina, T. V. Tolstik, A. M. Markin, A. N. Orekhov, А. И. Богатырева, Е. В. Герасимова, Т. В. Кириченко, Ю. В. Маркина, Т. В. Попкова, М. В. Шалыгина, Т. В. Толстик, А. М. Маркин, А. Н. Орехов

Contributors: Работа выполнена при финансовой поддержке Российского научного фонда, грант № 22-15-00199 «Механизмы хронизации воспаления при аутоиммунных ревматических заболеваниях: роль митохондриальных мутаций и нарушения воспалительного ответа моноцитов».

Source: Rheumatology Science and Practice; Vol 61, No 6 (2023); 744-750 ; Научно-практическая ревматология; Vol 61, No 6 (2023); 744-750 ; 1995-4492 ; 1995-4484

Subject Terms: MCP-1, systemic lupus erythematosus, systemic scleroderma, monocyte activation, proinflammatory cytokines, TNF-α, IL-1β, системная красная волчанка, системная склеродермия, активация моноцитов, провоспалительные цитокины, ФНО-α, ИЛ-1β

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3474/2334; Kouchit Y, Morand L, Martis N. Mortality and its risk factors in critically ill patients with connective tissue diseases: A meta-analysis. Eur J Intern Med. 2022;98:83-92. doi:10.1016/j.ejim.2022.02.006; Насонов ЕЛ, Лила АМ, Дубинина ТВ, Никитинская ОА, Амирджанова ВН. К 60-летию журнала «Научно-практическая ревматология» Достижения ревматологии в начале XXI века. Научно-практическая ревматология. 2022;60(1): 5-20. doi:10.47360/1995-4484-2022-5-20; Ahsan H. Selfie: Autoimmunity, boon or bane. J Immunoassay Immunochem. 2017;38(3):235-246. doi:10.1080/15321819.2017.1319861; Yang S, Zhao M, Jia S. Macrophage: Key player in the pathogenesis of autoimmune diseases. Front Immunol. 2023;14;14:1080310. doi:10.3389/fimmu.2023.1080310; Насонов ЕЛ, Авдеева АС. Интерлейкин 18 при иммуновоспалительных ревматических заболеваниях и COVID-19. Научно-практическая ревматология. 2022;60(2):195-204. doi:10.47360/1995-4484-2022-195-204; Ma WT, Gao F, Gu K, Chen DK. The role of monocytes and macrophages in autoimmune diseases: A comprehensive review. Front Immunol. 2019;10:1140. doi:10.3389/fimmu.2019.01140; Navegantes KC, de Souza Gomes R, Pereira PAT, Czaikoski PG, Azevedo CHM, Monteiro MC. Immune modulation of some autoimmune diseases: The critical role of macrophages and neutrophils in the innate and adaptive immunity. J Transl Med. 2017;15(1):36. doi:10.1186/s12967-017-1141-8; Pang J, Koh TJ. Proliferation of monocytes and macrophages in homeostasis, infection, injury and disease. J Leukoc Biol. 2023;9:qiad093. doi:10.1093/jleuko/qiad093; Герасимова ЕВ, Попкова ТВ. Функциональные нарушения макрофагов при ревматоидном артрите и атеросклерозе. Научно-практическая ревматология. 2018;56(4):486-493. doi:10.14412/1995-4484-2018-486-493; Prajzlerová K, Kryštůfková O, Komarc M, Mann H, Hulejová H, Petrovská N, et al. The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. Rheumatology (Oxford). 2021;60(4):1823-1831. doi:10.1093/rheumatology/keaa518; Wang Y, Han CC, Cui D, Li Y, Ma Y, Wei W. Is macrophage polarization important in rheumatoid arthritis? Int Immunopharmacol. 2017;50:345-352. doi:10.1016/j.intimp.2017.07.019; Byrne JC, Ní Gabhann J, Lazzari E, Mahony R, Smith S, Stacey K, et al. Genetics of SLE: Functional relevance for monocytes/macrophages in disease. Clin Dev Immunol. 2012;2012:582352. doi:10.1155/2012/582352; Kwant LE, Vegting Y, Tsang-A-Sjoe MWP, Kwakernaak AJ, Vogt L, Voskuyl AE, et al. Macrophages in lupus nephritis: Exploring a potential new therapeutic avenue. Autoimmun Rev. 2022;21(12):103211. doi:10.1016/j.autrev.2022.103211; Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128. doi:10.1186/ar3066; Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi:10.1002/art.27584; Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473; van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11): 1747-1755. doi:10.1136/annrheumdis-2013-204424; Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. doi:10.3389/fimmu.2019.00119; Goldring SR. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol. 2002;14(4):406-410. doi:10.1097/00002281-200207000-00013; Lama M, Sarkar R, Ghosh B. Serum cytokine profiles in patients with rheumatoid arthritis before and after treatment with methotrexate. J Interferon Cytokine Res. 2023;43(8):344-350. doi:10.1089/jir.2023.0078; Лапкина НА, Баранов АА, Абайтова НЕ, Левшин НЮ, Авдеева АС, Леонтьева ЕА, и др. Динамика клинических проявлений и концентрации цитокинов у больных ревматоидным артритом на фоне терапии тофацитинибом. Научно-практическая ревматология. 2021;59(6):693-699. doi:10.47360/1995-4484-2021-693-699; Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, et al. Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: The role of adipokines in scleroderma. Int J Rheum Dis. 2012;15(4):374-379. doi:10.1111/j.1756-185X.2012.01755.x; Zhao R, Zhou H, Su SB. A critical role for interleukin-1β in the progression of autoimmune diseases. Int Immunopharmacol. 2013;17(3):658-669. doi:10.1016/j.intimp.2013.08.012; Voronov E, Dayan M, Zinger H, Gayvoronsky L, Lin JP, Iwakura Y, et al. IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw. 2006;17(2):109-116.; Italiani P, Manca ML, Angelotti F, Melillo D, Pratesi F, Puxeddu I, et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):27. doi:10.1186/s13075-018-1525-z; Mähönen K, Hau A, Bondet V, Duffy D, Eklund KK, Panelius J, et al. Activation of NLRP3 inflammasome in the skin of patients with systemic and cutaneous lupus erythematosus. Acta Derm Venereol. 2022;102:adv00708. doi:10.2340/actadv.v102.2293; Moadab F, Khorramdelazad H, Abbasifard M. Role of CCL2/ CCR2 axis in the immunopathogenesis of rheumatoid arthritis: Latest evidence and therapeutic approaches. Life Sci. 2021;269:119034. doi:10.1016/j.lfs.2021.119034; Kuuliala K, Kuuliala A, Hämäläinen M, Koivuniemi R, Kautiainen H, Moilanen E, et al. Impaired Akt phosphorylation in monocytes of patients with rheumatoid arthritis. Scand J Immunol. 2017;85(2):155-161. doi:10.1111/sji.12521

Availability: https://rsp.mediar-press.net/rsp/article/view/3474
https://doi.org/10.47360/1995-4484-2023-744-750

Thrombotic antiphospholipid syndrome: Recurrent thromboses ; Тромботический антифосфолипидный синдром: рецидивы тромбозов

Authors: Tatiana M. Reshetnyak, Fariza A. Cheldieva, Svetlana I. Glukhova, Kamila S. Nurbaeva, Nataliya V. Seredavkina, Mariya V. Cherkasova, Alexander M. Lila, Evgeny L. Nasonov, Т. М. Решетняк, Ф. А. Чельдиева, С. И. Глухова, К. С. Нурбаева, Н. В. Середавкина, М. В. Черкасова, А. М. Лила, Е. Л. Насонов

Contributors: Статья подготовлена в рамках темы ФГБНУ НИИР им. В.А. Насоновой FURS-2022-003 (№ 122040400024-7), и исследование одобрено локальным этическим комитетом.

Source: Rheumatology Science and Practice; Vol 62, No 4 (2024); 408–417 ; Научно-практическая ревматология; Vol 62, No 4 (2024); 408–417 ; 1995-4492 ; 1995-4484

Subject Terms: антитела к комплексу фосфатидилсерин/протромбин, antiphospholipid antibodies, recurrent thromboses, systemic lupus erythematosus, antibodies to cardiolipin, antibodies to ß2-glycoprotein 1, antibodies to phosphatidylserine/prothrombin complex, антифосфолипидные антитела, рецидивы тромбозов, системная красная волчанка, антитела к кардиолипину, антитела к бета-2-гликопротеину 1

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3608/2390; Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. doi:10.14412/19954484-2014-56-71.; Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x; Насонов ЕЛ (ред.). Антифосфолипидный синдром. М.:Литте рра;2004. [Nasonov EL (ed.). Antiphospholipid syndrome. Moscow:Litterra;2004 (In Russ.)].; Решетняк ТМ, Чельдиева ФА, Нурбаева КС, Лила АМ, Насонов ЕЛ. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;4:4-21. doi:10.25555/THR.2020.4.0940.; Bazzan M, Vaccarino A, Stella S, Sciascia S, Montaruli B, Bertero MT, et al.; Piedmont APS Consortium. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). Lupus. 2016;25(5):479-485. doi:10.1177/0961203315617538; Brey RL, Muscal E, Chapman J. Antiphospholipid antibodies and the brain: A consensus report. Lupus. 2011;20(2):153-157. doi:10.1177/0961203310396748; Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: Advances in diagnosis, pathogenesis, and management. BMJ. 2023;380:e069717. doi:10.1136/bmj-2021-069717; Taraborelli M, Reggia R, Dall’Ara F, Fredi M, Andreoli L, Gerosa M, et al. Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study. J Rheumatol. 2017;44(8):1165-1172. doi:10.3899/jrheum.161364; Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT; Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320-2324. doi:10.1182/bloodadvances.2017008185; Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: The global anti-phospholipid syndrome score. Rheumatology (Oxford). 2013;52(8):1397-1403. doi:10.1093/rheumatology/kes388; Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S, et al. The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol. 2017;240:72-77. doi:10.1016/j.ijcard.2017.02.155; Чельдиева ФА, Решетняк ТМ, Шумилова АА, Нурбаева КС, Черкасова МВ, Лила АМ, и др. Общий индекс антифосфолипидного синдрома (GAPSS) у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2022; 60(5):546-553. doi:10.47360/1995-4484-2022-546-553; Abu-Zeinah G, Oromendia C, DeSancho MT. Thrombotic risk factors in patients with antiphospholipid syndrome: A single center experience. J Thromb Thrombolysis. 2019;48(2):233-239. doi:10.1007/s11239-019-01836-7; Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood. 2003;101(5):1827-1832. doi:10.1182/blood-2002-02-0441; Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Arthritis Care Res (Hoboken). 2013;65(11):1869-1873. doi:10.1002/acr.22066; Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117(12):997-1002. doi:10.7326/0003-4819-117-12-997; Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al.; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576-584. doi:10.1001/jama.291.5.576; Janardhan V, Wolf PA, Kase CS, Massaro JM, D’Agostino RB, Franzblau C, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: The Framingham cohort and offspring study. Stroke. 2004;35(3):736-741. doi:10.1161/01.STR.0000117575.48205.2D; Arvanitakis Z, Brey RL, Rand JH, Schneider JA, Capuano AW, Yu L, et al. Relation of antiphospholipid antibodies to postmortem brain infarcts in older people. Circulation. 2015;131(2):182-189. doi:10.1161/CIRCULATIONAHA.114.012479; Anand P, Mann SK, Fischbein NJ, Lansberg MG. Bilateral internal carotid artery occlusion associated with the antiphospholipid antibody syndrome. Case Rep Neurol. 2014;6(1):50-54. doi:10.1159/000360473; Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N. Neurological manifestations in patients with antiphospholipid syndrome. Iran J Neurol. 2013;12(4):172-175.; Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928; Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473; Решетняк ТМ, Чельдиева ФА, Черкасова МВ, Лила АМ. Клиническое значение антител к комплексу фосфатидилсерин/протромбин. Современная ревматология. 2022;16(2):8186. doi:10.14412/1996-7012-2022-2-81-86; Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al.; ACR/EULAR APS Classification Criteria Collaborators. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023;75(10):1687-1702. doi:10.1002/art.42624; Zhang S, Wu Z, Li P, Bai Y, Zhang F, et al. Evaluation of the clini cal performance of a novel chemiluminescent immunoassay for detection of anticardiolipin and anti-beta2-glycoprotein 1 antibodies in the diagnosis of antiphospholipid syndrome. Medicine (Baltimore). 2015;94(46):e2059. doi:10.1097/MD.0000000000002059; Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3(2):75-84. doi:10.5152/eurjrheum.2015.0085; Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213; Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19):2151-2160. doi:10.1182/blood-2017-09-805689; Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242. doi:10.1111/j.1538-7836.2009.03674.x; Foddai SG, Radin M, Cecchi I, Rubini E, Barinotti A, Alba P, et al. 2023 ACR/EULAR classification criteria in existing research cohorts: An international study. Rheumatology (Oxford). 2024 Jan 30:keae 058. doi:10.1093/rheumatology/keae058; Cheldieva FA, Shumilova AA, Cherkasova MV, Glukhova SI, Lila AM, Nasonov EL, et al. Risk factors and recurrent thrombosis in primary antiphospholipid syndrome. Explor Immunol. 2023;3:475-489. doi:10.37349/ei.2023.00114; Dufrost V, Darnige L, Reshetnyak T, Vorobyeva M, Jiang X, Yan XX, et al. New insights into the use of direct oral anticoagulants in non-high risk thrombotic APS patients: Literature review and subgroup analysis from a meta-analysis. Curr Rheumatol Rep. 2020;22(7):25. doi:10.1007/s11926-020-00901-y; Correa RCR, Franco CJV, Muñoz-Grajales C, Peñaranda LFP, Hernández JD, Padilla LMR, et al. Use of factor Xa inhibitors in antiphospholipid antibodies syndrome: A series of seven cases. Revista Colombiana de Reumatología. 2018;25(1):16-21. doi:10.1016/j.rcreu.2017.07.004; Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17(10):1011-1021. doi:10.1016/j.autrev.2018.04.009; Селиверстов ЕИ, Лобастов КВ, Илюхин ЕА, Апханова ТВ, Ахметзянов РВ, Ахтямов ИФ, и др. Профилактика, диагностика и лечение тромбоза глубоких вен. Рекомендации российских экспертов. Флебология. 2023;17(3):152-296. doi:10.17116/flebo202317031152; Navarro-Carpentieri D, Del Carmen Castillo-Hernandez M, Majluf-Cruz K, Espejo-Godinez G, Carmona-Olvera P, Moreno- Hernandez M, et al. Impact of classical risk factors for arterial or venous thrombosis in patients with antiphospholipid syndrome. Clin Appl Thromb Hemost. 2018;24(5):834-840. doi:10.1177/1076029617727859; Решетняк ТМ, Середавкина НВ, Мач ЭС, Александрова ЕН, Новиков АА, Черкасова МВ, и др. Cубклинические и клинические проявления атеросклероза при антифосфолипидном синдроме. Терапевтический архив. 2008;80(10):6067.; Berman H, Ugarte-Gil MF, Espinosa G, Tаssies D, Monteagudo J, Reverter JC, et al. Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome? Clin Exp Rheumatol. 2013;31(6):926-932.; Diz-Kucukkaya R, Hancer VS, Artim-Esen B, Pekcelen Y, Inanc M. The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis. 2010;29(3):303-309. doi:10.1007/s11239-009-0356-9; Решетняк ТМ, Патрушев ЛИ, Стукачева ЕА, Мирошников АИ, Тихонова ТЛ, Насонов ЕЛ, и др. Мутации Leiden, G 20210A в гене протромбина и антфосфолипидные антитела при системной красной волчанке и антифосфолипидном синдроме. Терапевтический архив. 2000;72(5):34-38.

Availability: https://rsp.mediar-press.net/rsp/article/view/3608
https://doi.org/10.47360/1995-4484-2024-408-417

Risk factors for severe COVID-19 in patients with rheumatic diseases ; Факторы риска тяжелого течения COVID-19 у больных ревматическими заболеваниями

Authors: A. N. Kulikov, N. V. Muravyeva, B. S. Belov, А. Н. Куликов, Н. В. Муравьева, Б. С. Белов

Contributors: Исследование выполнено в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (№ государственного задания 1021051503137-7).

Source: Rheumatology Science and Practice; Vol 62, No 1 (2024); 24-31 ; Научно-практическая ревматология; Vol 62, No 1 (2024); 24-31 ; 1995-4492 ; 1995-4484

Subject Terms: АНЦА-ассоциированные васкулиты, COVID-19, epidemiology, risk factors, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, ankylosing spondylitis, ANCA-associated vasculitis, эпидемиология, факторы риска, ревматоидный артрит, системная красная волчанка, системная склеродермия, анкилозирующий спондилит

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3511/2347; The top 10 causes of death. URL: https://www.who.int/newsroom/fact-sheets/detail/the-top-10-causes-of-death (Accessed: 12th December 2023).; WHO Director-General’s opening remarks at the media briefing – 5 May 2023. URL: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarksat-the-media-briefing---5-may-2023 (Accessed: 12th December 2023).; Chandel A, Leazer S, Alcover KC, Farley J, Berk J, Jayne C, et al. Intensive care and organ support related mortality in patients with COVID-19: A systematic review and meta-analysis. Crit Care Explor. 2023;5(3):e0876. doi:10.1097/CCE.0000000000000876; Глыбочко ПВ, Фомин ВВ, Моисеев СВ, Авдеев СН, Яворский АГ, Бровко МЮ, и др. Исходы у больных с тяжелым течением COVID-19, госпитализированных для респираторной поддержки в отделения реанимации и интенсивной терапии. Клиническая фармакология и терапия. 2020;29(3):25-36. doi:10.32756/0869-5490- 2020-3-25-36; Chen Z, Peng Y, Wu X, Pang B, Yang F, Zheng W, et al. Comorbidities and complications of COVID-19 associated with diseaseseverity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis.Front Public Health. 2022;10:923485. doi:10.3389/fpubh.2022.923485; Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al.Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449-1458. doi:10.1002/jmv.26424; Бекетова ТВ, Бабак ВВ, Супрун МД. Течение и исходы COVID-19 у пациентов с АНЦА-ассоциированными системными васкулитами, получающих лечение генно-инженерными биологическими препаратами (ритуксимаб, меполизумаб): итоги первых 8 месяцев пандемии. Научно-практическая ревматология. 2021;59(1):37-46. doi:10.47360/1995-4484-2021-37-46; Королев МА, Летягина ЕА, Сизиков АЭ, Богодерова ЛА, Убшаева ЮБ, Омельченко ВО, и др. Иммуновоспалительные ревматические заболевания и COVID-19: анализ клинических исходов по данным регистра пациентов Новосибирской области, получающих терапию генно-инженерными биологическими препаратами. Терапевтический архив. 2022;94(5):636-641. doi:10.26442/00403660.2022.05.201502; Мазуров ВИ, Беляева ИБ, Саранцева ЛЕ, Чудинов АЛ, Октябрьская ИВ, Башкинов РА, и др. Оценка влияния новой коронавирусной инфекции на клиническое течение ревматических заболеваний в реальной клинической практике. Медицинский алфавит. 2023;(9):7-16. doi:10.33667/2078-5631-2023-9-7-16; Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies. BMJ Open. 2021;11(1):e044640. doi:10.1136/bmjopen-2020-044640; Watson A, Wilkinson TMA. Respiratory viral infections in the elderly. Ther Adv Respir Dis. 2021;15:1753466621995050. doi:10.1177/1753466621995050; Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020; Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020; 369:m1985. doi:10.1136/bmj.m1985; Böhm M, Frey N, Giannitsis E, Sliwa K, Zeiher AM. Coronavirus disease 2019 (COVID-19) and its implications for cardiovascular care: Expert document from the German Cardiac Society and the World Heart Federation. Clin Res Cardiol. 2020;109(12):1446-1459. doi:10.1007/s00392-020-01656-3; Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855. doi:10.1186/s12879-021-06536-3; Wang L, Li X, Chen H, Yan S, Li D, Gong Z, et al. Coronavirus disease 19 infection does not result in acute kidney injury: An analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51(5):343-348. doi:10.1159/000507471; Singh R, Rathore SS, Khan H, Karale S, Chawla Y, Iqbal K, et al. Association of obesity with COVID-19 severity and mortality: An updated systemic review, meta-analysis, and meta-regression. Front Endocrinol (Lausanne). 2022;13:780872. doi:10.3389/fendo.2022.780872; Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: Angiotensinconverting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905-919. doi:10.1007/s10096-020-04138-6; Liew JW, Bhana S, Costello W, Hausmann JS, Machado PM, Robinson PC, et al. The COVID-19 Global Rheumatology Alliance: Evaluating the rapid design and implementation of an international registry against best practice. Rheumatology (Oxford). 2021;60(1):353-358. doi:10.1093/rheumatology/keaa483; Wallace ZS, Bhana S, Hausmann JS, Robinson PC, Sufka P, Sirotich E, et al. The Rheumatology Community responds to the COVID-19 pandemic: The establishment of the COVID-19 Global Rheumatology Alliance. Rheumatology (Oxford). 2020;59(6):1204-1206. doi:10.1093/rheumatology/keaa191; Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physicianreported registry. Ann Rheum Dis. 2020;79(7):859-866. doi:10.1136/annrheumdis-2020-217871; Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi:10.1136/annrheumdis2020-219498; Schäfer M, Strangfeld A, Hyrich KL, Carmona L, Gianfrancesco M, Lawson-Tovey S, et al. Response to: “Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician reported registry’” by Mulhearn et al. Ann Rheum Dis. 2023;82(5):e116. doi:10.1136/annrheumdis-2021-220134; Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-1146. doi:10.1136/annrheumdis-2021-220418; Kokkotis G, Kitsou K, Xynogalas I, Spoulu V, Magiorkinis G, Trontzas I, et al. Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment Pharmacol Ther. 2022;55(2):154-167. doi:10.1111/apt.16717; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2021;80(4):527-538. doi:10.1136/annrheumdis-2020-218310; Shin JI, Kim SE, Lee MH, Kim MS, Lee SW, Park S, et al. COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26(10):3760-3770. doi:10.26355/eurrev_202205_28873; Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark. Rheumatology (Oxford). 2021;60(SI):SI59-SI67. doi:10.1093/rheumatology/keaa897; Spila Alegiani S, Crisafulli S, Giorgi Rossi P, Mancuso P, Salvarani C, Atzeni F, et al. Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology (Oxford). 2021;60(SI):SI25-SI36. doi:10.1093/rheumatology/keab348; Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. doi:10.47360/1995-4484-2021-239-254; Landewé RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester GRR, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: The November 2021 update. Ann Rheum Dis. 2022;81(12):1628-1639. doi:10.1136/annrheumdiеs-2021-222006; Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BK, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 3. Arthritis Rheumatol. 2021;73(2):e1-e12. doi:10.1002/art.41596; Белов БС, Каратеев АЕ. COVID-19: новый вызов ревматологам. Современная ревматология. 2020;14(2):110-116. doi:10.14412/1996-7012-2020-2-110-116; Ziade N, El Khoury B, Zoghbi M, Merheb G, Abi Karam G, Mroue K, et al. Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: The COMORD study. Sci Rep. 2020;10(1):7683. doi:10.1038/s41598-020-64732-8; Symmons DPM, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7(7):399-408. doi:10.1038/nrrheum.2011.75

Availability: https://rsp.mediar-press.net/rsp/article/view/3511
https://doi.org/10.47360/1995-4484-2024-24-31

Contraception for antiphospholipid syndrome and systemic lupus erythematosus (according to the recommendations of the European Alliance of Associations for Rheumatology/American College of Rheumatology, EULAR/ACR) ; Контрацепция при антифосфолипидном синдроме и системной красной волчанке (по рекомендациям Европейского альянса ревматологических ассоциаций/Американской коллегии ревматологов, EULAR/АCR)

Authors: T. M. Reshetnyak, S. B. Kertchelaeva, N. M. Kosheleva, Т. М. Решетняк, С. Б. Керчелаева, Н. М. Кошелева

Contributors: Статья подготовлена в рамках темы ФГБНУ НИИР им. В.А. Насоновой FURS-2022-003 (№ 122040400024-7).

Source: Rheumatology Science and Practice; Vol 62, No 1 (2024); 13-23 ; Научно-практическая ревматология; Vol 62, No 1 (2024); 13-23 ; 1995-4492 ; 1995-4484

Subject Terms: системная красная волчанка, contraceptive methods, hormonal contraceptives, antiphospholipid syndrome, systemic lupus erythematosus, методы контрацепции, гормональные контрацептивы, антифосфолипидный синдром

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3510/2346; Обоскалова ТА (ред). Методы контрацепции и критерии их применения. Учебное пособие. Екатеринбург;2019.; Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5-е издание, 2015». М.;2023.; Сухих ГТ, Прилепская ВН, Аганезова НВ, Андреева ЕН, Баранов ИИ, Долгушина НВ, и др. Контрацепция у женщин репродуктивного возраста. Учебное пособие. М.:Бином;2019.; Сумятина ЛВ. Современные гормональные контрацептивы: новые возможности выбора. Проблемы репродукции. 2014;(6): 46-48.; Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404. doi:10.1016/j.contraception.2011.01.021; Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam Plan Perspect. 1991;23(5):226-227,232.; Назарова НМ, Прилепская ВН. Эстроген-гестагенные рилизинг-системы: новый взгляд на контрацепцию (обзор литературы). Фарматека. 2009;(14):10-16.; Williams WV. Hormonal contraception and the development of autoimmunity: A review of the literature. Linacre Q. 2017;84(3): 275-295. doi:10.1080/00243639.2017.1360065; Iwata M, Oikawa Y, Shimizu Y, Sakashita N, Shoji A, Igarashi A, et al. Efficacy of low-dose estrogen-progestins and progestins in Japanese women with dysmenorrhea: A systematic review and network meta-analysis. Adv Ther. 2022;39(11):4892-4909. doi:10.1007/s12325-022-02298-9; Прилепская ВН. Новаринг – контрацепция, анатомия, сексология. Гинекология. 2004;6(6):306-308.; Прилепская ВН, Назарова НМ. Новые технологии в контрацепции: гормональные рилизинг-системы. Гинекология. 2005;7(1):41-44.; Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost. 2020;46(8):865-871. doi:10.1055/s-0040-1715793; Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: World Health Organization; 2015. https://ww.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/; Amy JJ, Tripathi V. Contraception for women: An evidence-based overview. BMJ. 2009;339:b2895. doi:10.1136/bmj.b2895; Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998-2007. doi:10.1056/NEJMoa1110855; Kavanaugh ML, Pliskin E. Use of contraception among reproductive-aged women in the United States, 2014 and 2016. F S Rep. 2020;1(2):83-93. doi:10.1016/j.xfre.2020.06.006; Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2020;72(4):461-488. doi:10.1002/acr.24130; Насонов ЕЛ (ред.). Антифосфолипидный синдром. М.:Литтерра;2004.; Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. doi:10.14412/1995-4484-2014-56-71; Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x; Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008;59(6):863-866. doi:10.1002/art.23712; Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty E, et al. Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality? Arthritis Care Res (Hoboken). 2011;63(3):358-365. doi:10.1002/acr.20402; Brunson MR, Klein DA, Olsen CH, Weir LF, Roberts TA. Postpartum contraception: Initiation and effectiveness in a large universal healthcare system. Am J Obstet Gynecol. 2017;217(1): 55.e1-55.e9. doi:10.1016/j.ajog.2017.02.036; Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, et al. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology (Oxford). 2019;58(7):1259-1267. doi:10.1093/rheumatology/kez014; DeNoble AE, Hall KS, Xu X, Zochowski MK, Piehl K, Dalton VK. Receipt of prescription contraception by commercially insured women with chronic medical conditions. Obstet Gynecol. 2014;123(6):1213-1220. doi:10.1097/AOG.0000000000000279; Champaloux SW, Tepper NK, Curtis KM, Zapata LB, Whiteman MK, Marchbanks PA, et al. Contraceptive use among women with medical conditions in a nationwide privately insured population. Obstet Gynecol. 2015;126(6):1151-1159. doi:10.1097/AOG.0000000000001134; Birru Talabi M, Clowse MEB, Blalock SJ, Moreland L, Siripong N, Borrero S. Contraception use among reproductive-age women with rheumatic diseases. Arthritis Care Res (Hoboken). 2019;71(8):1132-1140. doi:10.1002/acr.23724; Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1195-1199. doi:10.3899/jrheum.081194; Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56(7):2382-2391. doi:10.1002/art.22663; Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004;104(1):143-148. doi:10.1182/blood-2003-11-4085; Girolami A, Zanon E, Zanardi S, Saracino MA, Simioni P. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 1996;7(4):497-501. doi:10.1097/00001721-199606000-00011; Bacci S, Urquiola G, del Médico P, Sanabria JA, Bacci JC, Guzmán M, et al. Síndrome de Budd-Chiari, tromboembolismo pulmonar y trombosis venosa profunda, asociado con “anticoagulante lúpico” y uso reciente de anticonceptivos orales [Budd-Chiari syndrome, pulmonary thromboembolism, and deep venous thrombosis associated with “lupus anticoagulant” and recent use of oral contraceptives]. G E N. 1990;44(3):237-242 (In Spanish).; Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: A case-control study. Lancet Neurol. 2009;8(11):998-1005. doi:10.1016/S1474-4422(09)70239-X; Sammaritano LR.Which hormones and contraception for women with APS? Exogenous hormone use in women with APS. Curr Rheumatol Rep. 2021;23(6):44. doi:10.1007/s11926-021-01006-w; Iskander MK, Khan M. Chorea as the initial presentation of oral contraceptive related systemic lupus erythematosus. J Rheumatol. 1989;16(6):850-851.; Yamakami LY, de Araujo DB, Silva CA, Baracat EC, de Carvalho JF. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20(5):523-526. doi:10.1177/0961203310383300; Crétel E, Cacoub P, Huong DL, Gompel A, Amoura Z, Piette JC. Massive ovarian haemorrhage complicating oral anticoagulation in the antiphospholipid syndrome: A report of three cases. Lupus. 1999;8(6):482-485. doi:10.1177/096120339900800614; ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6):1453-1472. doi:10.1097/00006250-200606000-00055; Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: Efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus. 2006;15(12):877-880. doi:10.1177/0961203306071706; Rebelo RC, Pignaton E, Valeria Bahamondes M, Costallat LTL, Appenzeller S, Bahamondes L, et al. Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: Users of the 52-mg levonorgestrel-releasing intrauterine system. Arch Gynecol Obstet. 2019;299(6):1597-1605. doi:10.1007/s00404-019-05131-x; van Vlijmen EF, Veeger NJ, Middeldorp S, Hamulyák K, Prins MH, Büller HR, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: A rational approach to contraception. Blood. 2011;118(8):2055-2061;quiz 2375. doi:10.1182/blood-2011-03-345678; Klok FA, Barco S. Optimal management of hormonal contraceptives after an episode of venous thromboembolism. Thromb Res. 2019;181(Suppl 1):1-5. doi:10.1016/S0049-3848(19)30357-3; Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417-1425. doi:10.1182/blood2015-08-665927; Паневин ТС, Попкова ТВ, Решетняк ТМ, Кошелева НМ, Ледина АВ. Менопаузальная гормонотерапия при системной красной волчанке: Pro et contra. Научно-практическая ревматология. 2023;61(1):70-76. doi:10.47360/1995-4484-2023-70-76; The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. doi:10.1097/GME.0000000000000921; U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142(10):855-860.; Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427. doi:10.1016/s0140-6736(03)14065-2; Менопауза и климактерическое состояние у женщин: Клинические рекомендации МЗ РФ. М.;2021. [Menopause and climacteric condition in women. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow;2021 (In Russ.)].; Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al.; Women’s Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573-1580. doi:10.1001/jama.292.13.1573; Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;(7):CD004143. doi:10.1002/14651858; Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292(13):1581-1587. doi:10.1001/jama.292.13.1581; Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, et al.; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277-2286. doi:10.1111/j.1538-7836.2012.04919.x; Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. Circulation. 2005; 112(22):3495-3500. doi:10.1161/CIRCULATIONAHA.105.565556; Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002;116(4):851-854. doi:10.1046/j.0007-1048.2002.03356.x; Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation. 2007;115(7):840-845. doi:10.1161/CIRCULATIONAHA.106.642280; Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb Res. 2018;168:83-95. doi:10.1016/j.thromres.2018.06.014; Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ. 2008;336(7655):1227-1231. doi:10.1136/bmj.39555.441944.BE; Pinkerton JV, James AH. Management of menopausal symptoms for women who are at high risk of thrombosis. Clin Obstet Gynecol. 2018;61(2):260-268. doi:10.1097/GRF.0000000000000358; Krause MS, Nakajima ST. Hormonal and nonhormonal treatment of vasomotor symptoms. Obstet Gynecol Clin North Am. 2015;42(1):163-179. doi:10.1016/j.ogc.2014.09.008; Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis. JAMA. 2006;295(17):2057-2071. doi:10.1001/jama.295.17.2057; Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902;quiz 903-904. doi:10.1097/GME.0b013e3182a122c2; Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2018;26(6):603-610. doi:10.1097/GME.0000000000001284; de Melo AS, Dos Reis RM, Ferriani RA, Vieira CS. Hormonal contraception in women with polycystic ovary syndrome: Choices, challenges, and noncontraceptive benefits. Open Access J Contracept. 2017;8:13-23. doi:10.2147/OAJC.S85543; Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68-91. doi:10.1016/j.bpobgyn.2018.01.015; Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: A meta-analysis. Ann Surg Oncol. 2017;24(5):1322-1329. doi:10.1245/s10434-016-5699-9; Grandone E, Di Micco PP, Villani M, Colaizzo D, FernándezCapitán C, Del Toro J, et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: Data from the RIETE registry. Thromb Haemost. 2018;118(11):1962-1968. doi:10.1055/s-0038-1673402; Machin N, Ragni MV. Hormones and thrombosis: Risk across the reproductive years and beyond. Transl Res. 2020;225:9-19. doi:10.1016/j.trsl.2020.06.011; Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174(3):785-794. doi:10.1007/s10549-018-05086-8; Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: A cohort study. Ann Intern Med. 2018;169(4):205-213. doi:10.7326/M17-2785; Goldstein Z, Khan M, Reisman T, Safer JD. Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. J Blood Med. 2019;10:209-216. doi:10.2147/JBM.S166780; Duan B, Zhang Y, Wang X, Zhang Y, Hou Y, Bai J, et al. Effect of megestrol acetate combined with oral nutrition supplement in malnourished lung cancer patients: A single-center prospective cohort study. Front Nutr. 2021;8:654194. doi:10.3389/fnut.2021.654194; Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet. 1999;354(9190):1610. doi:10.1016/s0140-6736(99)03132-3; Аномальные маточные кровотечения. Клинические рекомендации МЗ РФ. М.;2021. [Abnormal uterine bleeding. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow;2021 (In Russ.)].

Availability: https://rsp.mediar-press.net/rsp/article/view/3510
https://doi.org/10.47360/1995-4484-2024-13-23

Features of B cell subsets in primary Sjogren’s syndrome and systemic lupus erythematosus ; Особенности субпопуляций В-лимфоцитов при болезни Шегрена и системной красной волчанке

Authors: S. S. Benevolenskaya, I. V. Kudriavtsev, M. K. Serebriakova, I. N. Grigor’yeva, E. S. Kuvardin, A. I. Budkova, S. V. Koniakhin, D. B. Zammoeva, D. B. Motorin, A. Yu. Zaritskey, I. Z. Gaydukova, E. K. Gaydukova, S. V. Lapin, A. L. Maslyanskiy, С. С. Беневоленская, И. В. Кудрявцев, М. К. Серебрякова, И. Н. Григорьева, Е. С. Кувардин, А. И. Будкова, С. В. Коняхин, Д. Б. Заммоева, Д. Б. Моторин, А. Ю. Зарицкий, И. З. Гайдукова, Е. К. Гайдукова, С. В. Лапин, А. Л. Маслянский

Contributors: Исследование выполнено при финансовой поддержке Министерства науки и высшего образования Российской Федерации (соглашение № 075-15-2022-301 от 20.04.2022)

Source: Rheumatology Science and Practice; Vol 62, No 5 (2024); 501-512 ; Научно-практическая ревматология; Vol 62, No 5 (2024); 501-512 ; 1995-4492 ; 1995-4484

Subject Terms: проточная цитометрия, B cells, systemic lupus erythematosus, primary Sjogren’s syndrome, flow cytometry, В-лимфоциты, системная красная волчанка, болезнь Шегрена

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3636/2404; Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017.; Pasoto SG, Adriano de Oliveira Martins V, Bonfa E. Sjögren’s syndrome and systemic lupus erythematosus: Links and risks. Open Access Rheumatol. 2019;11:33-45. doi:10.2147/OARRR.S167783; Ambrus JL, Suresh L, Peck A. Multiple roles for B-lymphocytes in Sjogren’s syndrome. J Clin Med. 2016;5(10):87. doi:10.3390/jcm5100087; Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest. 2002;109(1):59-68. doi:10.1172/JCI14121; Nocturne G, Seror R, Fogel O, Belkhir R, Boudaoud S, Saraux A, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren’s syndrome. Arthritis Rheumatol. 2015;67(12):3226-3233. doi:10.1002/art.39315; Carvajal Alegria G, Gazeau P, Hillion S, Daïen CI, Cornec DYK. Could lymphocyte profiling be useful to diagnose systemic autoimmune diseases? Clin Rev Allergy Immunol. 2017;53(2):219-236. doi:10.1007/s12016-017-8608-5; Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. doi:10.1002/art.40930; Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al.; International Sjögren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35-45. doi:10.1002/art.39859; Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al.; OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-2558. doi:10.1056/NEJMoa051135; Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): A user guide. RMD Open. 2015;1(1):e000022. doi:10.1136/rmdopen-2014-000022; Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al.; EULAR Sjögren’s Task Force. EULAR Sjogren’s syndrome patient reported index (ESSPRI): Development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis. 2011;70(6):968-972. doi:10.1136/ard.2010.143743; Зурочка АВ, Хайдуков СВ, Кудрявцев ИВ, Чернышев ВА. Проточная цитометрия в биомедицинских исследованиях. Екатеринбург:УрО РАН;2018.; Будкова АИ, Лапин СВ, Серебрякова МК, Кудрявцев ИВ, Тришина ИН, Маслянский АЛ, и др. Субпопуляционный состав В-клеток периферической крови у больных системной красной волчанкой. Медицинская иммунология. 2017;19(2):175-184.; Меснянкина АА, Соловьев СК, Александрова ЕН, Алексанкин АП, Супоницкая ЕВ, Елонаков АВ, и др. Динамика субпопуляции В-лимфоцитов у больных системной красной волчанкой на фоне терапии генно-инженерными биологическими препаратами. Научно-практическая ревматология. 2017;55(3):252-260.; Cornec D, Saraux A, Pers JO, Jousse-Joulin S, Marhadour T, Roguedas-Contios AM, et al. Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren’s syndrome. Arthritis Res Ther. 2014;16(1):R15. doi:10.1186/ar4442; Barcelos F, Martins C, Papoila A, Geraldes C, Cardigos J, Nunes G, et al. Association between memory B-cells and clinical and immunological features of primary Sjögren’s syndrome and Sicca patients. Rheumatol Int. 2018;38(6):1063-1073. doi:10.1007/s00296-018-4018-0; Ishioka-Takei E, Yoshimoto K, Suzuki K, Nishikawa A, Yasuoka H, Yamaoka K, et al. Increased proportion of a CD38highIgD+ B cell subset in peripheral blood is associated with clinical and immunological features in patients with primary Sjögren’s syndrome. Clin Immunol. 2018;187:85-91. doi:10.1016/j.clim.2017.10.008; Roberts ME, Kaminski D, Jenks SA, Maguire C, Ching K, Burbelo PD, et al. Primary Sjögren’s syndrome is characterized by distinct phenotypic and transcriptional profiles of IgD+ unswitched memory B cells. Arthritis Rheumatol. 2014;66(9):2558-2569. doi:10.1002/art.38734; Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000;165(10):5970-5979. doi:10.4049/jimmunol.165.10.5970; Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum. 2002;46(8):2160-2171. doi:10.1002/art.10445; Aqrawi LA, Brokstad KA, Jakobsen K, Jonsson R, Skarstein K. Low number of memory B cells in the salivary glands of patients with primary Sjögren’s syndrome. Autoimmunity. 2012;45(7):547-555. doi:10.3109/08916934.2012.712170; Mingueneau M, Boudaoud S, Haskett S, Reynolds TL, Nocturne G, Norton E, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren’s signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016;137(6):1809-1821.e12. doi:10.1016/j.jaci.2016.01.024; Wardowska A, Komorniczak M, Skoniecka A, Bułło-Piontecka B, Lisowska KA, Dębska-Ślizień MA, et al. Alterations in peripheral blood B cells in systemic lupus erythematosus patients with renal insufficiency. Int Immunopharmacol. 2020;83:106451. doi:10.1016/j.intimp.2020.106451; Супоницкая ЕВ, Алексанкин АП, Меснянкина АА, Александрова ЕН, Панафидина ТА, Соловьев СК. Характеристика субпопуляций В-лимфоцитов периферической крови у больных активной системной красной волчанкой. Клиническая лабораторная диагностика. 2017;62(7):418-422.; Enocsson H, Karlsson J, Li HY, Wu Y, Kushner I, Wetterö J, et al. The complex role of C-reactive protein in systemic lupus erythematosus. J Clin Med. 2021;10(24):5837. doi:10.3390/jcm10245837

Availability: https://rsp.mediar-press.net/rsp/article/view/3636
https://doi.org/10.47360/1995-4484-2024-501-512